A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
about
The role of late I Na in development of cardiac arrhythmiasRanolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivityPost-translational modifications of the cardiac Na channel: contribution of CaMKII-dependent phosphorylation to acquired arrhythmiasAnti-anginal and anti-ischemic effects of late sodium current inhibitionNovel pharmacological targets for the rhythm control management of atrial fibrillation.Excavatolide B Modulates the Electrophysiological Characteristics and Calcium Homeostasis of Atrial Myocytes.Pathophysiology of the cardiac late Na current and its potential as a drug target.The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure.Pharmacology of myocardial calcium-handling.Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review.Cardiac salvage by tweaking with beta-3-adrenergic receptors.Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.New and Emerging Therapies and Targets: Beta-3 Agonists.Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells.Ranolazine for the treatment of refractory angina in a veterans population.Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice.Clinical experience with ranolazine in a veteran population with chronic stable angina.Mechanisms and models of cardiac sodium channel inactivation.Cardiac beta3-adrenergic receptors in the clinical arena: the end of the beginning.Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertroph
P2860
Q26823149-F15C2F7D-DC90-440D-A114-BD361F0FA913Q28260201-203F593F-4B73-4BB4-8F8B-8E8A16404715Q28292930-774DB104-6C91-4081-8DC0-E069CB7BE65BQ35147202-C46C1246-34DD-438D-B469-BD74361DF264Q35489060-EC2F1539-DEED-4B7A-A4C9-6C9C7127DA48Q36260790-BFDD0575-39B0-409C-964E-0A2BD6E80F1EQ37276416-DB173E93-2406-422A-8036-CD44B7744F4EQ37345048-AE4CB7C4-E6D1-4D86-99A4-E15966EB70A0Q37812007-F3332981-7094-41AE-AEA1-DA7942B7FE0CQ38019446-8E30832B-B451-4439-88D2-380DAEF242B0Q38071920-E0DD29F0-80EC-4536-A651-8A6BA2CB345DQ38074900-AD811494-3621-4C35-A732-50379844CBD8Q38098955-62474D42-BEFA-4B0F-8F7D-B790D770814BQ38784206-1BC1B204-44B2-4400-A3D6-9A44CDD76F99Q38920729-0AA0B58D-EACA-406B-B2D3-464CDABABE0AQ39062830-13ADEA13-B187-4EFA-8BBF-C87D5894ABD2Q39270116-6F41BA2B-2616-40EE-A484-BA290F131F46Q43216084-EB064FA0-F0C1-48CE-AA23-3B924D6E33F6Q43669272-2542C8DF-201D-43F1-9ECC-9F9C665D820AQ45330316-B9E4CEB2-06AC-4717-8273-3B416616C0FCQ47758712-2A853004-A796-4017-A922-24D607163470Q53750512-A5264920-43AC-49FF-B937-793DEB708BD8Q56968615-69CF2B0B-5EB5-4E4A-A43E-9F2B3E89C25D
P2860
A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@en
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@nl
type
label
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@en
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@nl
prefLabel
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@en
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@nl
P2860
P1476
A novel mechanism for the trea ...... f late I(Na) using ranolazine.
@en
P2093
Lars S Maier
P2860
P304
P356
10.1097/FJC.0B013E3181A1B9E7
P407
P577
2009-10-01T00:00:00Z